Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab Combinations in B-Cell NHL
NCT03677141Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2019
- Primary completion
- Oct 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of mosunetuzumab in B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started Mar 2019; status: completed.
02
Drugs
mosunetuzumab
03
Conditions
B-cell non-Hodgkin lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03677141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03677141.